Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Trial Profile

A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evorpacept (Primary) ; Pembrolizumab (Primary) ; Rituximab (Primary) ; Trastuzumab (Primary) ; Cisplatin; Fluorouracil; Paclitaxel; Ramucirumab
  • Indications Adenocarcinoma; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Head and neck cancer; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Acronyms ASPEN-01
  • Sponsors ALX Oncology
  • Most Recent Events

    • 20 Jul 2023 Planned End Date changed from 1 Feb 2023 to 1 Feb 2024.
    • 01 Aug 2022 According to an ALX Oncology media release, based on results from this study the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to evorpacept, in combination with KEYTRUDA (pembrolizumab), for the first-line treatment of adult patients with PD-L1 positive advanced head and neck squamous cell carcinoma (HNSCC).
    • 20 Jul 2022 Planned End Date changed from 1 Dec 2022 to 1 Feb 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top